FibroGen Inc (FGEN)

Name: FibroGen Inc (FGEN) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: FibroGen Inc (FGEN)

Stock Card

$7.50

$-1.72 (-18.66%)

As on 05-Feb-2026 09:30EDT

Market cap

$39 Mln

Revenue (TTM)

$-118 Mln

P/E Ratio

P/B Ratio

53.8

Div. Yield

0 %

FibroGen (FGEN) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 7.50 High: 8.34

52 Week Range

Low: 4.85 High: 21.94

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-10.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.2
Debt to Equity

0
Book Value

$--
EPS

$52.2
Face value

--
Shares outstanding

4,045,445

10 Years Aggregate

CFO

$-672.00 Mln

EBITDA

$-1,430.64 Mln

Net Profit

$-1,556.34 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
FibroGen (FGEN)	-14.6	-18.1	-31.8	-35.2	-77.0	-64.1	-33.4
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 05-Feb-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
FibroGen (FGEN)	-33.7	-40.0	-94.5	13.6	-62.0	-13.5	-7.3
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
FibroGen (FGEN)	7.5	39.3	-118.1	215.7	109.1	--	--	53.8
Applied Therapeutics (APLT)	0.1	14.9	1.0	-18.1	-10,073.6	--	--	7.7
Salarius Pharmaceuticals (SLRX)	0.6	4.9	0.0	-5.0	-114,018.1	-232.2	--	1.1

Shareholding Pattern

View Details

About FibroGen (FGEN)

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl... hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Read more

CEO & Director

Mr. Thane Wettig
CEO & Director

Mr. Thane Wettig
Headquarters

San Francisco, CA
Website

https://www.fibrogen.com

FAQs for FibroGen (FGEN)

What is the current share price of FibroGen Inc (FGEN) Today?

The share price of FibroGen Inc (FGEN) is $7.50 (NASDAQ) as of 05-Feb-2026 09:30 EDT. FibroGen Inc (FGEN) has given a return of -76.97% in the last 3 years.

What is the current PB & PE ratio of FibroGen Inc (FGEN)?

Since, TTM earnings of FibroGen Inc (FGEN) is negative, P/E ratio is not available.
The P/B ratio of FibroGen Inc (FGEN) is 53.83 times as on 05-Feb-2026, a 939 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.